Illumina (NASDAQ:ILMN – Get Free Report) was downgraded by investment analysts at Barclays from an “equal weight” rating to ...

We recently published an article titled These 10 Companies Led Monday’s Downturn. In this article, we are going to take a ...

San Diego-based gene-sequencing giant Illumina got tangled in the United States’ trade tensions Tuesday as China placed the ...

The placement of Illumina in China's unreliable entity list could have disruptive implications. Read why I remain bullish on ...

Barclays downgraded Illumina (ILMN) to Underweight from Equal Weight with a price target of $100, down from $130. The firm sees greater risk to ...

Illumina has struggled to boost sales and consistently deliver positive earnings. Its Q4 report was largely a disappointment, and management's 2025 guidance came in below Wall Street's ...

Illumina is down 15.2% since the beginning of the year, and at $111.06 per share, it is trading 28.4% below its 52-week high of $155.15 from November 2024. Investors who bought $1,000 worth of ...

TD Cowen downgraded Illumina (ILMN) to Hold from Buy with a price target of $140, down from $177. Accelerating high throughput next-generation ...

For all of last year, Illumina’s net loss grew 5% from $1.161 billion to $1.223 billion, on revenue that fell 3% from $4.505 ...

Analysts said the move comes amid rising trade tensions with the U.S. and as Illumina faces stiff competition in China’s ...

Illumina (NASDAQ:ILMN – Get Free Report) is anticipated to announce its earnings results after the market closes on Thursday, February 13th. Analysts expect the company to announce earnings of $0.92 ...

Puneet Souda, a research analyst for Leerink Partners, wrote in a research note Tuesday that Illumina’s inclusion on the list “appears more permanent posturing by China” rather than ...